MicroRNAs help to predict disease progression in brain tumours

15 Jun 2016

Scientists at the Helmholtz Zentrum München and the Ludwig Maximilians University of Munich (LMU) have developed a new method of predicting disease progression in glioblastoma patients who have undergone standard treatment.

Their findings, published in the journal Oncotarget, show that four miRNAs may hold the vital clue.

An application for the corresponding patent has already been filed.

Roughly one-fifth of all brain tumours diagnosed by doctors are glioblastomas.

This aggressive and most common type of brain

However, molecular markers could help them to make the right treatment decision.

A team of researchers led by Dr. Kristian Unger, Deputy Head of the Radiation Cytogenetics Research Unit (headed by Prof. Dr. Horst Zitzelsberger) at the Helmholtz Zentrum München, and Prof. Dr. Claus Belka, Director of the Clinic and Policlinic for Radiotherapy and Radiation Oncology at the University of Munich's Grosshadern Hospital (member of the DKTK cancer research consortium), has now succeeded in identifying specific miRNAs that could serve as biomarkers for disease progression.

In collaboration with the Institute of Neurology (Edinger Institute) at the University Hospital Frankfurt, researchers examined the composition of miRNAs in samples from 36 patients from whom tumour material had been removed during treatment, and whose subsequent course of treatment had been well documented. 

"We repeatedly detected four miRNAs in Karim-Maximilian Niyazi, senior physician at Grosshadern, and first author of the study.

Based on their data, the scientists calculated a risk score to distinguish two patient groups who were undergoing standard treatment and whose life expectancy varied by about five months.

In order to corroborate their findings, they used data obtained from a further 58 independent samples.

Here, too, they found that the composition of the miRNAs altered, the worse the prospects of a successful treatment outcome were.

The scientists are confident that their observations will have more than mere theoretical implications. 

For this reason, they have already filed an application for the corresponding patent.

"To date, only a few prognostic and predictive factors for glioblastoma have been identified," says research team leader Unger. "Our method could be used to identify candidates for alternative or intensified treatment options, as it is highly unlikely that patients with a high risk score would benefit from standard therapy."

Since tumor tissue would generally be removed immediately, a corresponding analysis would be relatively easy to conduct and would not require any additional time or expense, the researchers note.

Whether the miRNAs have a malignant function in the cancer cells themselves or are merely an indirect marker remains to be clarified.

In initial studies, however, the scientists have shown that miRNAs could possibly even play a role in various processes of tumour development.

Source: Oncotarget